Drug Trial Radar · NCT02956629
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
282
Actual
Start
Nov 16, 2016
Primary completion
Dec 22, 2017
Study completion Mar 5, 2018
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 7, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a nonrandomized, multi-site, open-label trial to evaluate a novel two-drug combination regimen (uprifosbuvir \[MK-3682\] 450 mg + ruzasvir \[RZR; MK-8408\] 180 mg once daily \[q.d.\] for 12 weeks) in male and female treatment-naïve (TN) or treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6 who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C) and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV) co-infection will be enrolled.
Conditions
- Hepatitis C
Interventions
UprifosbuvirDrug
Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
RuzasvirDrug
Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
RibavirinDrug
RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Completing Study Therapy (SVR12)Time frame: 12 weeks after completing study therapy (Week 24)
- Percentage of Participants Experiencing an Adverse Event (AE)Time frame: Up to Week 14
- Percentage of Participants Experiencing an AE of Clinical Importance (ECI)Time frame: Up to Week 14
- Percentage of Participants Experiencing a Serious Adverse Event (SAE)Time frame: Up to Week 14
- Percentage of Participants Experiencing a Drug-related AETime frame: Up to Week 14
- Percentage of Participants Experiencing a Drug-related SAETime frame: Up to Week 14
- Percentage of Participants Discontinuing Study Therapy Due to an AETime frame: Up to Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.